Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers

An isolated recombinant oncolytic adenovirus, wherein the recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus and the genome of the recombinant oncolytic adenovirus is integrated with a polynucleotide sequence encoding an exogenous shRNA capable of inhibiting the expression of PDL1 in tumor cells;

• wherein the genome of the recombinant oncolytic adenovirus is lacking the E1B19K gene, the E1B55K gene, and all the genes in the E3 region and comprises a E1A protein-coding sequence and the E1A protein-coding sequence is under the control of a promoter;
• and wherein the polynucleotide sequence encoding the exogenous shRNA is as shown in any one of SEQ ID NOs:
• 16, 19, and 22.

A kit of combinational drugs with synergistic effects for treatment of tumors and/or cancers, comprising separate containers containing respectively and independently a recombinant oncolytic adenovirus and NK cells, and instructions specifying the timing and routes of administration;

• wherein the recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus and the genome of the recombinant oncolytic adenovirus is integrated with a polynucleotide sequence encoding an exogenous shRNA capable of inhibiting the expression of PDL1 in tumor cells;
• wherein the polynucleotide sequence encoding the exogenous shRNA is as shown in any one of SEQ ID NOs:
• 16, 19, and 22.